110 related articles for article (PubMed ID: 19174038)
1. [Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences].
Hokland P; Ommen HB; Nyvold CG; Stentoft J; Braendstrup K; Andersen BL; Mikkelsen LS; Ostergaard M
Ugeskr Laeger; 2009 Jan; 171(4):232-5. PubMed ID: 19174038
[TBL] [Abstract][Full Text] [Related]
2. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.
Bartley PA; Ross DM; Latham S; Martin-Harris MH; Budgen B; Wilczek V; Branford S; Hughes TP; Morley AA
Int J Lab Hematol; 2010 Dec; 32(6 Pt 1):e222-8. PubMed ID: 20491997
[TBL] [Abstract][Full Text] [Related]
3. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
4. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.
Ou J; Vergilio JA; Bagg A
Am J Hematol; 2008 Apr; 83(4):296-302. PubMed ID: 17957805
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence in situ hybridization analysis of minimal residual disease and the relevance of the der(9) deletion in imatinib-treated patients with chronic myeloid leukemia.
Calabrese G; Fantasia D; Di Gianfilippo R; Stuppia L; Di Lorenzo R; Palka G
Haematologica; 2006 Jul; 91(7):994-5. PubMed ID: 16818290
[TBL] [Abstract][Full Text] [Related]
6. Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia.
Menif S; Zarrouki S; Jeddi R; ben Alaya N; Ali ZB; Ben Abid H; Hdeiji S; Elloumi M; Khlif A; Meddeb B; Dellagi K
Pathol Biol (Paris); 2009 Jul; 57(5):388-91. PubMed ID: 18387753
[TBL] [Abstract][Full Text] [Related]
7. CML: imatinib mesylate (Glivec) or something else?
Ghosh A
Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
[No Abstract] [Full Text] [Related]
8. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
[TBL] [Abstract][Full Text] [Related]
9. Detection and monitoring of minimal residual disease by quantitative real-time PCR.
Schüler F; Dölken G
Clin Chim Acta; 2006 Jan; 363(1-2):147-56. PubMed ID: 16154122
[TBL] [Abstract][Full Text] [Related]
10. Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.
Tefferi A; Kantarjian H
Am J Hematol; 2008 Mar; 83(3):175-7. PubMed ID: 18181199
[No Abstract] [Full Text] [Related]
11. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
Minami Y; Naoe T
Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
[TBL] [Abstract][Full Text] [Related]
12. The detection and significance of minimal residual disease in chronic myeloid leukemia.
Radich JP
Medicina (B Aires); 2000; 60 Suppl 2():66-70. PubMed ID: 11188935
[TBL] [Abstract][Full Text] [Related]
13. [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].
Yagasaki F; Niwa T; Abe A; Ishikawa M; Kato C; Ogura K; Sasaki H; Kyo T; Jinnai I; Bessyo M; Miyamura K
Rinsho Ketsueki; 2009 Jun; 50(6):481-7. PubMed ID: 19571508
[TBL] [Abstract][Full Text] [Related]
14. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
[TBL] [Abstract][Full Text] [Related]
15. Imatinib: a second look. Longer follow-up in chronic myeloid leukaemia: clear advantages.
Prescrire Int; 2008 Dec; 17(98):226-8. PubMed ID: 19415889
[TBL] [Abstract][Full Text] [Related]
16. [Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation].
Hokland P; Nyvold CG; Stentoft J; Ommen HB; Ebbesen LH; Braendstrup K; Andersen BL; Mikkelsen LS; Ostergaard M
Ugeskr Laeger; 2009 Jan; 171(4):229-31. PubMed ID: 19174037
[TBL] [Abstract][Full Text] [Related]
17. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.
Tefferi A; Dewald GW; Litzow ML; Cortes J; Mauro MJ; Talpaz M; Kantarjian HM
Mayo Clin Proc; 2005 Mar; 80(3):390-402. PubMed ID: 15757021
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
[No Abstract] [Full Text] [Related]
19. Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients.
Sumi M; Tauchi T; Sashida G; Shoji N; Gotoh A; Itoh Y; Miyazawa K; Kimura Y; Ohyashiki JH; Ohyashiki K
Clin Lab Haematol; 2005 Dec; 27(6):416-7. PubMed ID: 16307547
[No Abstract] [Full Text] [Related]
20. Monitoring of minimal residual disease in chronic myeloid leukemia.
Faderl S; Hochhaus A; Hughes T
Hematol Oncol Clin North Am; 2004 Jun; 18(3):657-70, ix-x. PubMed ID: 15271398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
